Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2025 | Mkt Perform → Underperform | Barrington Research | |
| 3/7/2025 | $43.00 | Hold → Buy | Lake Street |
| 6/13/2023 | $36.00 | Hold → Buy | Needham |
| 2/13/2023 | Buy → Hold | Needham | |
| 2/4/2022 | $70.00 → $58.00 | Buy | Needham |
| 11/10/2021 | $76.00 → $70.00 | Buy | Needham |
| 9/8/2021 | $68.00 → $76.00 | Buy | Needham |
Barrington Research downgraded Surmodics from Mkt Perform to Underperform
Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00
Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00
8-K - SURMODICS INC (0000924717) (Filer)
10-Q - SURMODICS INC (0000924717) (Filer)
8-K - SURMODICS INC (0000924717) (Filer)
Surmodics, Inc. (NASDAQ:SRDX) ("Surmodics" or the "Company"), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the "District Court") has denied a request by the U.S. Federal Trade Commission (the "FTC") and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR LLC ("GTCR") from consummating the proposed acquisition of the Company by an affiliate of GTCR (the "Merger"). Consummation of the Merger remains subject to a Temporary Restraining Order under which the parties to the Merger agree not to
Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom had symptoms lasting more than two weeks before intervention with the Pounce™ Platform. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at the 23rd Annual VIVA Conference in Las Vegas, NV. PROWL natio
PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Updated safety and performance data from 160 patients with symptomatic infrainguinal vessels will be shared. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Sean Lyden, Dr. Joseph Campbell, and Dr. Peter Monteleone, will present and discuss updated safety and performance data from the PROWL registry on 160 patients with symptomatic lower extremity (infrainguinal) vessels treated with the Pounce™ Thrombectomy Platform. The presentati
4 - SURMODICS INC (0000924717) (Issuer)
4 - SURMODICS INC (0000924717) (Issuer)
4 - SURMODICS INC (0000924717) (Issuer)
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $29.6 million, an increase of 1% year-over-year GAAP loss of $(5.3) million, compared to $(7.6) million in the prior-year period Adjusted EBITDA(2) of $3.4 million, compared to $1.6 million in the pr
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the third quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil
SC 13G/A - SURMODICS INC (0000924717) (Subject)
SC 13G/A - SURMODICS INC (0000924717) (Subject)
SC 13G/A - SURMODICS INC (0000924717) (Subject)